450-P: N-Terminal Pro-B Type Natriuretic Peptide Concentrations in Diabetic Cardiomyopathy—Baseline Data from the ARISE-HF Trial

• Published in: Diabetes (New York, N.Y.) Vol. 72; no. Supplement_1; p. 1
• Main Authors: BUTLER, JAVED, DEL PRATO, STEFANO, EZEKOWITZ, JUSTIN, IBRAHIM, NASRIEN E., LAM, CAROLYN S., PERFETTI, RICCARDO, ROSENSTOCK, JULIO, WILSON TANG, W.H., URBINATI, ALESSIA, ZANNAD, FAIEZ, JANUZZI, JAMES L.
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 20.06.2023
• Subjects: Aldehyde reductase; Blood pressure; Cardiomyopathy; Congestive heart failure; Diabetes; Diabetes mellitus (non-insulin dependent); Echocardiography; Exercise; Peptides; Physical activity; Physical fitness; Physical training; Population studies; Ventricle

Background: Diabetic Cardiomyopathy (DbCM) is a form of Stage B heart failure (HF). Concentrations of N-terminal pro-B type natriuretic peptide (NT-proBNP) may predict risk for HF progression in persons with DbCM. The ARISE-HF study (NCT04083339) is evaluating efficacy of AT-001, a highly selective...